Table 1 Summary of the eligible studies on NLR in predicting survival treatment response, and diagnosis, in patients with ovarian cancer

Cho et al. [38], 2009; Badora-Rybicka et al.[70], 2016; Wang et al. [49], 2016; Nakamura et al. [53], 2016; Miao et al. [50], 2016; Feng et al. [71], 2016; Li et al. [34], 2017; Farolfi et al. [39], 2018; Zhou et al. [51], 2018; Pinto et al. [54], 2018; Pinto et al. [54], 2018; Komura et al. [48], 2018; Kim et al. [55], 2018; Baert et al. [52], 2018; Ceran et al. [40], 2019; Yoshida et al. [36], 2019; Salman et al. [41], 2020; Henriksen et al. [43], 2020; Farolfi et al. [44], 2020; Nguyen et al. [42], 2020; John-Olabode et al. [45], 2021; Liontos et al. [46], 2021

OCP: received operations, with stage IIIC and IV received NACT, with recurrence treated with chemotherapy;

EOCP: underwent elective surgery, receiving platinum-taxane CT after surgery, in FIGO stage III-IV treated with first-line CT or in CTB, with FIGO stage IIIC underwent PDS, received NACT, received their complete primary treatment;

HGSOCP: underwent surgery (PDS);

OCCCP: underwent surgery with stage I–II

Predicting survival: OS, PFS, mortality within 100 days of the failure of final‑line CT

Ashrafganjoe et al. [56], 2016; Farolfi et al. [39], 2018; Boland et al. [58], 2019; Henriksen et al. [43], 2020; Chen et al. [60], 2020; Nguyen et al. [42], 2020; Winarno et al. [59], 2021; Sastra et al. [57], 2022

OCP: recurrent and received CT;

EOCP: underwent primary staging exploratory laparotomy, in FIGO stage III-IV treated with first-line CT or CTB; received ICB, underwent platinum CT after cytoreduction surgery;

HGSOCP: underwent surgery (PDS);

OCCCP: with IC-IV stage

Predicting treatment response: surgical outcome, efficacy of CT, early discontinuation of ICB; platinum resistance, 30-day postoperative morbidity

Yildirim et al. [62], 2014; Yildirim et al. [63], 2015; Seckin et al. [26], 2015; Polat et al. [30], 2016; Wu et al. [64], 2019; Eo et al. [65], 2018; Li et al. [66], 2021; Yun et al. [67], 2022

OCP: with documented benign and with malignant adnexal masses underwent primary surgery; patients with adnexal masses underwent surgical resection; patients had borderline, patients had benign, and patients had malignant mucinous ovarian tumors; women with sonographically detected ovarian tumor; OCP, patients with benign ovarian disease, and healthy controls;

EOCP: underwent surgery; patients with benign ovarian masses and EOCP underwent surgery

Predicting diagnosis: malignant or not, malignant degree, histotypes, benign or borderline tumors